Menu
Menu
The OneSource Connect was developed by Quantum Leap Healthcare Collaborative (QLHC) as a strategic initiative to streamline the capture of clinical and research data at the point-of-care from Electronic Health Records (EHR) systems for secondary uses, such as clinical trials and registries.
OneSource is the only integrated EHR/electronic data capture (EDC) solution that captures regulatory-grade data from Epic and Cerner EHRs with both Clinical Research Coordinator (CRC) and patient-mediated data access. The platform includes best-in-class solutions for electronic data capture (EDC), electronic patient reported outcomes (ePRO), biospecimen, trial randomization, safety reporting and site payment systems that are fully integrated.
Data capture, cleaning and validation represent a considerable portion of the costs of conducting clinical trials. Manual data abstraction from electronic health records to trial-specific electronic case report forms is time consuming and error-prone; the associated costs and staffing requirements also represent a significant barrier for clinical sites to participate in clinical trial enrollment. Recent developments, including the emergence of modern clinical trial designs that require rapid access to study data and the urgency of public health crises such as the COVID-19 pandemic have underscored the need to re-engineer current data capture and management approaches and tools for clinical trials.
The OneSource Connect platform is currently deployed at over 25 sites participating in the multicenter, phase 2 I-SPY 2 TRIAL and I-SPY-COVID-19 adaptive platform trial. Data auto-captured from these sites has led to data entry efficiencies and downstream cost savings in cleaning and source data verification (SDV). OneSource has the additional benefits of low implementation times and reusability across sites compared to other EHR integration approaches.
For more information on how OneSource Connect can be leveraged for your clinical trial or research network. Please reach out to Adam Asare, Chief Data Officer, at aasare@quantumleaphealth.org
OneSource AI provides access to secure analytic workspaces and data for partners to explore and develop models and AI algorithms leveraging data from the I-SPY family of trials. Datasets include clinical, imaging, biomarker and sequencing data.
Full end-to-end platform services for that study to happen inside the environment. OneSource AI’s platform houses over 7,000 H & E image files used by pathologists to collaboratively review whole slide images (WSI) and share their findings in real-time. Ee-identified images are available for wider use to researchers across healthcare, academia, and industry to carry out novel research in a secure and audited environment. Leveraging the benefits of cloud computing, this enables researchers to have real-time access to a secure and scalable platform that can help them to manage and analyze large amounts of data more efficiently.
OneSource AI plays a pivotal role in enabling novel AI/ML research to identify patterns and trends in the data that may not be immediately apparent. The platform supports researchers in making more accurate predictions about the efficacy of different treatments and therapies, which can ultimately lead to better outcomes for patients.
OneSource AI has the potential to revolutionize medical research by providing researchers with access to a wealth of data and advanced analytics tools that can help them to identify new treatments and therapies more effectively and collaboratively than ever before.
For more information on how OneSource AI can help with analytical modeling and AI algorithm development leveraging data from the I-SPY family of trials p lease reach out to Adam Asare, Chief Data Officer, at aasare@quantumleaphealth.org
As Patient Engagement Lead at Quantum Leap, I manage follow-up data projects for the I-SPY 2 Trial, develop strategies to strengthen patient engagement, and oversee the I-SPY Advocate group. After six successful years raising funds to support Quantum’s mission, I embraced this new role last summer, drawn by the opportunity to make a direct impact on the patients we serve. Each day brings new challenges and insights, and I especially enjoy supporting and collaborating with our inspiring I-SPY Advocates.
Outside of work, I am pursuing a Master of Public Administration with a focus on nonprofit management at SF State. I’m passionate about trail running, skiing, live music, camping, traveling, and collegiate gymnastics—my daughter competes at Oregon State. For the past 5 years, I have volunteered with SF CASA as a mentor to an incredible 18-year-old foster youth whose resilience continually reminds me of life’s true priorities.
Carolyn Clark Beedle, a 2023 breast cancer survivor, joined the advocate program after successful completion of treatment with the UCSF Breast Oncology Program. Her experience working with a patient advocate during her TNBC treatment led to an understanding that empowering women to advocate for their own health and healthcare will contribute to improved health outcomes and broader access to care. Carolyn began advocating for cancer patients and their families during her treatment, now is a member of the Breast Science Advocacy Core (BSAC) with the UCSF Breast Oncology Program, and currently shares information and research with CFNP associates at La Clinica in the Bay Area to inform and empower their patient population.
Carolyn is continuing her on the ground training as an advocate reviewer with both Quantum Health and BSAC and is enrolled in the Patient Advocacy Training in Health Science course with Stanford Medicine. Her 30+ career in corporate marketing/communications, program development and non-profit leadership augmented by her breast cancer treatment experience serves Carolyn well in representing and communicating the patient voice and perspective.
She received her BA (History/English Lit) and MA (Public History/Research and Record Management) from the University of San Diego, is a proud fifth generation San Franciscan, and active board member with numerous non-profits that support social work and the arts.
Silver Alkhafaji is a PhD candidate in the Pharmaceutical Sciences and Pharmacogenomics (PSPG) program at UCSF. She received her Bachelor of Science in Chemical Biology from UC Berkeley. Prior to UCSF, she worked in the Clinical Pharmacology Department at Genentech. Silver’s current research focuses on non-invasive liquid biopsies to predict response and side effects of immunotherapies and endocrine therapies in early-stage breast cancer participants in I-SPY 2.
Silver is interested in clinical outcomes research to advance precision medicine and improve cancer patients’ quality of life. She is passionate about health equity, inclusive research, patient advocacy, and women’s health.
Silver volunteers at the Patient and Family Cancer Support Center at UCSF where she assists in patient navigation and connecting patients and their families with resources that improve their healthcare experience while receiving cancer treatments and/or during survivorship.
Through her DEI work in her PhD program, Silver raises awareness around issues related to social justice and community building through organizing community-centered events. Additionally, she is a member of the Life Sciences Career Advisory Council at Thrive Scholars, where she enjoys supporting college students of color from economically disadvantaged communities in providing the opportunities they need to thrive at top colleges and in high-trajectory careers.
Silver is a member of the American Association of University Women (AAUW) Alameda Branch where she focuses her efforts on increasing membership of community college women coming from exceptional backgrounds: student parents, low-income, and first-generation college students.
In her free time, she writes poetry and prose on emotional healing, radical acceptance, and patience. Writing has helped her process difficult situations and connect with people on a deeper level.
Jane is a breast cancer survivor and advocate dedicated to positively impacting the lives of women affected by the disease. Diagnosed with triple negative breast cancer in 2012, she participated in the I-SPY 2 trial at UCSF and has been cancer free for more than ten years.
Her advocacy journey began in 2003 at UCSF as a volunteer with the Patient and Family Cancer Support Center and Decision Support Services and she previously managed the Peer Support program at UCSF. Drawing on her experience in marketing and media strategy, she uses her skills to make a meaningful impact by supporting advocacy and research that improves outcomes for women living with breast cancer.
In March of 2023 , Jan was diagnosed with a large aggressive triple negative breast cancer and informed that her cancer was the” bad girl” of cancer and offered standard chemotherapy for 24 weeks. Devasted by the diagnosis Jan felt like she had a dire prognosis. After seeking several opinions, she opted to join a Clinical Trial program for her treatment. The trial consisted of significantly less chemotherapy, and monitored closely over a 12-week period, The data predicted a complete pathological response , and she then went immediately to surgery. Pathology reports supported that she had a successful outcome reaching PCR meaning the tumor was gone, and no residual cancer was found in the surrounding tissue or lymph nodes. Jan was thrilled when her surgeon advised her of the results. The experience made Jan want to give back and share information that she received when she was at a critical juncture in her diagnosis. She is so passionate about making sure that everyone knows that the standard of care is one treatment option.
As she says, “ clinical trials have to be on the table” Because she achieved PCR, she expects a great outcome. She wants to share her story and encourage other women to strongly consider and participate in clinical trials. Jan is a UCSF Patient Advocate, involved in several programs they lead. Jan also is a BLACC Cab Member. Jan recently was in Washington DC to participate on a panel on Clinical Trials for ISPY at the National Press Club. UCSF will be hosting the RISE Up For Breast Cancer event where Jan will share her experience with clinical trials.
Deb is a connector who founded Patient Advocates in Research (PAIR) “where research meets reality,” bringing ideas and people together for medical advances that offer real results for diverse patients and families.
Her vast experience between the worlds of tech, communication, strategy, management, policy, and equity bridges gaps between patients, scientists, medical providers, payers, governments, and non-profits.
Deb infuses patient engagement into projects, gathers relevant patient input, and encompasses many diseases, programs and policies at grassroots, national and international levels through companies, academia, and governments.
Key patient insights are delivered throughout discovery, development, clinical trials, results reporting, data-sharing, standards, genomics, and into practice.
Her experience spans translational and clinical research, epidemiology, health outcomes, and health delivery research with academia, federal agencies, companies, and patient communities.
